Truist Financial’s Vir Biotechnology VIR Stock Holding History

Truist Financial’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,115	Closed	-$67K	–	2917
2025 Q4	$67K	Hold	11,115	–	–	﹤0.01%	2697
2025 Q3	$63.5K	Buy	+11,115	New	+$56.8K	﹤0.01%	2659

Other funds holding VIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Truist Financial's VIR Position: Q1 2026 in Review

Truist Financial sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 11,115 shares — an estimated $67K sold.

Truist Financial first reported a position in VIR in Q3 2025 and held it in 2 quarters. The position peaked at $67K in Q4 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

Truist Financial reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
Truist Financial sold 11,115 Vir Biotechnology shares in Q1 2026, an estimated $67K.
Truist Financial first reported a position in Vir Biotechnology in Q3 2025 and held it in 2 quarters.
Truist Financial's Vir Biotechnology position peaked at $67K in Q4 2025.
251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.